Several previously published studies [43–45] pointed on the fact that diabetes modulates the activity of CYP enzymes; hence, this modulation can, in theory, lead to changed rivaroxaban activity in T2D subjects. The gene discussed is PPIG; the disease is type 2 diabetes mellitus.